Profound Medical Corp Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
63.3%projected annual EPS growth
Analyst Coverage
5analysts covering
FY EPS (est.)
-$0.84next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results and Business Update | 16 Nov 2026 |
Monitoring Framework
Key Performance Indicators
TULSA-PRO Installed Base Quarterly80.0Target: 120 installations by the end of 2026
Quarterly Revenue Quarterly5.3MTarget: Approximately CAD 25 million for full-year 2026
Gross Margin Quarterly7,200.0%Target: 70% or higher for full-year 2026
Watch Items
- CAPTAIN Trial 12-Month Oncologic DataTrigger: Release of 12-month follow-up oncologic outcomes comparing TULSA to robotic radical prostatectomyAction: Evaluate clinical efficacy and potential impact on inclusion in standard prostate cancer treatment guidelines
- Payer Coverage ExpansionTrigger: Adoption of TULSA Procedure coverage by major private insurance providers (following Humana's addition of 6.9M lives)Action: Assess commercial adoption rate and utilization trends at installed sites
Research as of 20 Jun 2026